Search research articles
Contact Us
Filters
Showing results (231-240 of 245) with videos related to
Page
of 25
Sort By:
Journal of Medicinal Chemistry
|
February 2, 2022
Discovery of Non-Nucleotide Small-Molecule STING Agonists <i>via</i> Chemotype Hybridization
Emily C Cherney, Liping Zhang, Julian Lo, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 3, 2014
Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors
James J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry
|
December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors
John Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Journal of Medicinal Chemistry
|
February 16, 2021
Tricyclic-Carbocyclic RORγt Inverse Agonists-Discovery of BMS-986313
Michael G Yang, Myra Beaudoin-Bertrand, Zili Xiao, et al.
Journal of Medicinal Chemistry
|
September 1, 2010
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases
Chunjian Liu, James Lin, Stephen T Wrobleski, et al.
Journal of Medicinal Chemistry
|
March 19, 2004
N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent
Raj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry
|
September 3, 2015
Correction to N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent
Raj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry
|
August 23, 2002
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities
Kyoung Soon Kim, S David Kimball, Raj N Misra, et al.
Journal of Medicinal Chemistry
|
March 6, 2009
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily
Gretchen M Schroeder, Yongmi An, Zhen-Wei Cai, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|
August 15, 2019
Interdisciplinary consensus on indications for transfemoral transcatheter aortic valve implantation (TF-TAVI) : Joint Consensus Document of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte e.V. (ALKK) and cooperating Cardiac Surgery Departments
Wolfgang von Scheidt, A Welz, M Pauschinger, et al.
Page
of 25
Search research articles
Search
Showing results (231-240 of 245) with videos related to
Sort By:
Page
of 25
Journal of Medicinal Chemistry
|
February 2, 2022
Discovery of Non-Nucleotide Small-Molecule STING Agonists <i>via</i> Chemotype Hybridization
Emily C Cherney, Liping Zhang, Julian Lo, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 3, 2014
Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors
James J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry
|
December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors
John Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Journal of Medicinal Chemistry
|
February 16, 2021
Tricyclic-Carbocyclic RORγt Inverse Agonists-Discovery of BMS-986313
Michael G Yang, Myra Beaudoin-Bertrand, Zili Xiao, et al.
Journal of Medicinal Chemistry
|
September 1, 2010
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases
Chunjian Liu, James Lin, Stephen T Wrobleski, et al.
Journal of Medicinal Chemistry
|
March 19, 2004
N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent
Raj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry
|
September 3, 2015
Correction to N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent
Raj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry
|
August 23, 2002
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities
Kyoung Soon Kim, S David Kimball, Raj N Misra, et al.
Journal of Medicinal Chemistry
|
March 6, 2009
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily
Gretchen M Schroeder, Yongmi An, Zhen-Wei Cai, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|
August 15, 2019
Interdisciplinary consensus on indications for transfemoral transcatheter aortic valve implantation (TF-TAVI) : Joint Consensus Document of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte e.V. (ALKK) and cooperating Cardiac Surgery Departments
Wolfgang von Scheidt, A Welz, M Pauschinger, et al.
Page
of 25